English

ABIONYX Pharma

ESEF

Report (type unavailable) · filed 2026-03-18

Annual consolidated revenue for 2025: about EUR 4.063M, using the latest reported figures. The previous period, 2024, was about EUR 4.551M.

Inspect reported changes Compare with another company Historical disclosures Segments

Watchlist

Latest fiscal year

Revenue

4.06 million EUR

2025 · EUR

Exact inputs and evidence

Revenue: 4063000 EUR Source

Operating margin

-136.3%

2025 · %

Exact inputs and evidence

Operating Income: -5538000 EUR Source
Revenue: 4063000 EUR Source

Operating cash flow

-2.93 million EUR

2025 · EUR

Exact inputs and evidence

Operating Cash Flow: -2933000 EUR Source

Free cash flow

-3.18 million EUR

2025 · EUR

Exact inputs and evidence

Operating Cash Flow: -2933000 EUR Source
Capital Expenditure: 242000 EUR Source

Cash and cash equivalents: 3.52 million EUR 2025-12-31 Source
Exact value

3521000 EUR
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-03-18.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2025-12-31
Operating income: 6 of 11 periods available· newest 2025-12-31
net income: No compatible figures in this window
Operating cash flow: 6 of 11 periods available· newest 2025-12-31
Capital expenditure: 6 of 11 periods available· newest 2025-12-31
Total assets: 5 of 11 periods available· newest 2025-12-31
liabilities: No compatible figures in this window
Current assets: 5 of 11 periods available· newest 2025-12-31
Current liabilities: 5 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-10.7%

Prior period

EUR 4.55 million

2024-01-01 – 2024-12-31
Current period

EUR 4.06 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

4063000 − 4551000 = -488000 EUR

4551000 EUR · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
4063000 EUR · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ABIONYX Pharma · 2025-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Year-over-year change in Revenue: -488000 EUR Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 4063000 EUR (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9126849 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0 Input fundies:Revenue: 4551000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9127447 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+EUR 701,000

Prior period

−EUR 3.63 million

2024-01-01 – 2024-12-31
Current period

−EUR 2.93 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-2933000 − -3634000 = 701000 EUR

-3634000 EUR · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-2933000 EUR · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ABIONYX Pharma · 2025-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Year-over-year change in Operating cash flow: 701000 EUR Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -2933000 EUR (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9321047 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0 Input fundies:OperatingCashFlow: -3634000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9321697 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+255.9%

Prior period

EUR 68,000

2024-01-01 – 2024-12-31
Current period

EUR 242,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

242000 − 68000 = 174000 EUR

68000 EUR · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
242000 EUR · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ABIONYX Pharma · 2025-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Year-over-year change in Capital expenditure: 174000 EUR Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 242000 EUR (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9329846 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0 Input fundies:CapitalExpenditure: 68000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9330504 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Net income.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue EUR 4.06 million 100% of revenue
Operating costs Derived EUR 9.6 million 236% of revenue
Operating income −EUR 5.54 million −136% of revenue
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow −EUR 2.93 million −72% of revenue
Capital expenditure EUR 242,000 6% of revenue
Free cash flow Derived −EUR 3.18 million −78% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	675000	6627000 Derived	-5952000	Unavailable	Unavailable	-6858000 Derived	Source 2021-01-01 – 2021-12-31: 675000 EUR Inspect Revenue Open source 2021-01-01 – 2021-12-31: -5952000 EUR Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -6692000 EUR Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 166000 EUR Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	5252000	9361000 Derived	-4109000	Unavailable	Unavailable	-3524000 Derived	Source 2022-01-01 – 2022-12-31: 5252000 EUR Inspect Revenue Open source 2022-01-01 – 2022-12-31: -4109000 EUR Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -3359000 EUR Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 165000 EUR Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	4640000	8052000 Derived	-3412000	Unavailable	Unavailable	-3802000 Derived	Source 2023-01-01 – 2023-12-31: 4640000 EUR Inspect Revenue Open source 2023-01-01 – 2023-12-31: -3412000 EUR Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -3698000 EUR Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 104000 EUR Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	4551000	9016000 Derived	-4465000	Unavailable	Unavailable	-3702000 Derived	Source 2024-01-01 – 2024-12-31: 4551000 EUR Inspect Revenue Open source 2024-01-01 – 2024-12-31: -4465000 EUR Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -3634000 EUR Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 68000 EUR Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	4063000	9601000 Derived	-5538000	Unavailable	Unavailable	-3175000 Derived	Source 2025-01-01 – 2025-12-31: 4063000 EUR Inspect Revenue Open source 2025-01-01 – 2025-12-31: -5538000 EUR Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -2933000 EUR Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 242000 EUR Inspect Capital Expenditure Open source

Amounts are exact, in EUR.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

EUR 4.1M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(EUR)	Source evidence
20212021-12-31	Revenue	675000	Revenue: 675000 Open source
20222022-12-31	Revenue	5252000	Revenue: 5252000 Open source
20232023-12-31	Revenue	4640000	Revenue: 4640000 Open source
20242024-12-31	Revenue	4551000	Revenue: 4551000 Open source
20252025-12-31	Revenue	4063000	Revenue: 4063000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-10.7% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 675000 Open source
20222022-12-31	Year over year	678.1%	Revenue: 5252000 Open source Revenue: 675000 Open source
20232023-12-31	Year over year	-11.7%	Revenue: 4640000 Open source Revenue: 5252000 Open source
20242024-12-31	Year over year	-1.9%	Revenue: 4551000 Open source Revenue: 4640000 Open source
20252025-12-31	Year over year	-10.7%	Revenue: 4063000 Open source Revenue: 4551000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -136.3% 2025

Free cash flow margin -78.1% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	-881.8%	Operating Income: -5952000 Open source Revenue: 675000 Open source
20222022-12-31	Operating margin	-78.2%	Operating Income: -4109000 Open source Revenue: 5252000 Open source
20232023-12-31	Operating margin	-73.5%	Operating Income: -3412000 Open source Revenue: 4640000 Open source
20242024-12-31	Operating margin	-98.1%	Operating Income: -4465000 Open source Revenue: 4551000 Open source
20252025-12-31	Operating margin	-136.3%	Operating Income: -5538000 Open source Revenue: 4063000 Open source
2021-12-31	Net margin	Not reported	Revenue: 675000 Open source
2022-12-31	Net margin	Not reported	Revenue: 5252000 Open source
2023-12-31	Net margin	Not reported	Revenue: 4640000 Open source
2024-12-31	Net margin	Not reported	Revenue: 4551000 Open source
2025-12-31	Net margin	Not reported	Revenue: 4063000 Open source
20212021-12-31	Free cash flow margin	-1,016%	Revenue: 675000 Open source Operating Cash Flow: -6692000 Open source Capital Expenditure: 166000 Open source
20222022-12-31	Free cash flow margin	-67.1%	Revenue: 5252000 Open source Operating Cash Flow: -3359000 Open source Capital Expenditure: 165000 Open source
20232023-12-31	Free cash flow margin	-81.9%	Revenue: 4640000 Open source Operating Cash Flow: -3698000 Open source Capital Expenditure: 104000 Open source
20242024-12-31	Free cash flow margin	-81.3%	Revenue: 4551000 Open source Operating Cash Flow: -3634000 Open source Capital Expenditure: 68000 Open source
20252025-12-31	Free cash flow margin	-78.1%	Revenue: 4063000 Open source Operating Cash Flow: -2933000 Open source Capital Expenditure: 242000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

EUR -2.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(EUR)	Source evidence
20212021-12-31	Operating cash flow	-6692000	Operating Cash Flow: -6692000 Open source
20222022-12-31	Operating cash flow	-3359000	Operating Cash Flow: -3359000 Open source
20232023-12-31	Operating cash flow	-3698000	Operating Cash Flow: -3698000 Open source
20242024-12-31	Operating cash flow	-3634000	Operating Cash Flow: -3634000 Open source
20252025-12-31	Operating cash flow	-2933000	Operating Cash Flow: -2933000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

EUR -3.2M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(EUR)	Source evidence
20212021-12-31	Free cash flow	-6858000	Operating Cash Flow: -6692000 Open source Capital Expenditure: 166000 Open source
20222022-12-31	Free cash flow	-3524000	Operating Cash Flow: -3359000 Open source Capital Expenditure: 165000 Open source
20232023-12-31	Free cash flow	-3802000	Operating Cash Flow: -3698000 Open source Capital Expenditure: 104000 Open source
20242024-12-31	Free cash flow	-3702000	Operating Cash Flow: -3634000 Open source Capital Expenditure: 68000 Open source
20252025-12-31	Free cash flow	-3175000	Operating Cash Flow: -2933000 Open source Capital Expenditure: 242000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2021-12-31	Liabilities / assets	Not reported	Total Assets: 21832000 Open source
2022-12-31	Liabilities / assets	Not reported	Total Assets: 15823000 Open source
2023-12-31	Liabilities / assets	Not reported	Total Assets: 14834000 Open source
2024-12-31	Liabilities / assets	Not reported	Total Assets: 13541000 Open source
2025-12-31	Liabilities / assets	Not reported	Total Assets: 13115000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.06× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	1.93×	Current Assets: 13011000 Open source Current Liabilities: 6747000 Open source
20222022-12-31	Current assets / current liabilities	1.49×	Current Assets: 7572000 Open source Current Liabilities: 5094000 Open source
20232023-12-31	Current assets / current liabilities	1.75×	Current Assets: 6886000 Open source Current Liabilities: 3925000 Open source
20242024-12-31	Current assets / current liabilities	1.58×	Current Assets: 5859000 Open source Current Liabilities: 3705000 Open source
20252025-12-31	Current assets / current liabilities	1.06×	Current Assets: 5467000 Open source Current Liabilities: 5163000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	Unavailable Not reported for this period.	−EUR 599,000 Exact value Exact value: -599000 EUR 2020-01-01 – 2020-12-31: -599000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIONYX Pharma · 2020-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Operating Cash Flow: -599000 EUR Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: -599000 EUR (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2021-12-31/ESEF/FR/0/abionyxpharma-2021-12-31AR.zip#9239414 Filing: 969500785J7VIC5YPC96-2021-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	EUR 103,000 Exact value Exact value: 103000 EUR 2020-01-01 – 2020-12-31: 103000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIONYX Pharma · 2020-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Capital Expenditure: 103000 EUR Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 103000 EUR (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2021-12-31/ESEF/FR/0/abionyxpharma-2021-12-31AR.zip#9243529 Filing: 969500785J7VIC5YPC96-2021-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	−EUR 702,000 Calculation and evidence -599000 − 103000 EUR Exact free cash flow: -702000 EUR 2020-01-01 – 2020-12-31: -599000 EUR · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 103000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIONYX Pharma · 2020-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Free cash flow: -702000 EUR Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -599000 EUR (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2021-12-31/ESEF/FR/0/abionyxpharma-2021-12-31AR.zip#9239414 Filing: 969500785J7VIC5YPC96-2021-12-31-ESEF-FR-0 Input fundies:CapitalExpenditure: 103000 EUR (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2021-12-31/ESEF/FR/0/abionyxpharma-2021-12-31AR.zip#9243529 Filing: 969500785J7VIC5YPC96-2021-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	Unavailable Not reported for this period.	−EUR 6.69 million Exact value Exact value: -6692000 EUR 2021-01-01 – 2021-12-31: -6692000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIONYX Pharma · 2021-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Operating Cash Flow: -6692000 EUR Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: -6692000 EUR (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2022-12-31/ESEF/FR/0/abionyxpharma-2022-12-31AR.zip#8258265 Filing: 969500785J7VIC5YPC96-2022-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	EUR 166,000 Exact value Exact value: 166000 EUR 2021-01-01 – 2021-12-31: 166000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIONYX Pharma · 2021-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Capital Expenditure: 166000 EUR Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 166000 EUR (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2022-12-31/ESEF/FR/0/abionyxpharma-2022-12-31AR.zip#8262710 Filing: 969500785J7VIC5YPC96-2022-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	−EUR 6.86 million Calculation and evidence -6692000 − 166000 EUR Exact free cash flow: -6858000 EUR 2021-01-01 – 2021-12-31: -6692000 EUR · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 166000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIONYX Pharma · 2021-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Free cash flow: -6858000 EUR Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6692000 EUR (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2022-12-31/ESEF/FR/0/abionyxpharma-2022-12-31AR.zip#8258265 Filing: 969500785J7VIC5YPC96-2022-12-31-ESEF-FR-0 Input fundies:CapitalExpenditure: 166000 EUR (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2022-12-31/ESEF/FR/0/abionyxpharma-2022-12-31AR.zip#8262710 Filing: 969500785J7VIC5YPC96-2022-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	Unavailable Not reported for this period.	−EUR 3.36 million Exact value Exact value: -3359000 EUR 2022-01-01 – 2022-12-31: -3359000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIONYX Pharma · 2022-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Operating Cash Flow: -3359000 EUR Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: -3359000 EUR (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2023-12-31/ESEF/FR/0/abionyxpharma-2023-12-31AR.zip#14785852 Filing: 969500785J7VIC5YPC96-2023-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	EUR 165,000 Exact value Exact value: 165000 EUR 2022-01-01 – 2022-12-31: 165000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIONYX Pharma · 2022-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Capital Expenditure: 165000 EUR Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 165000 EUR (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2023-12-31/ESEF/FR/0/abionyxpharma-2023-12-31AR.zip#14794466 Filing: 969500785J7VIC5YPC96-2023-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	−EUR 3.52 million Calculation and evidence -3359000 − 165000 EUR Exact free cash flow: -3524000 EUR 2022-01-01 – 2022-12-31: -3359000 EUR · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 165000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIONYX Pharma · 2022-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Free cash flow: -3524000 EUR Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3359000 EUR (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2023-12-31/ESEF/FR/0/abionyxpharma-2023-12-31AR.zip#14785852 Filing: 969500785J7VIC5YPC96-2023-12-31-ESEF-FR-0 Input fundies:CapitalExpenditure: 165000 EUR (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2023-12-31/ESEF/FR/0/abionyxpharma-2023-12-31AR.zip#14794466 Filing: 969500785J7VIC5YPC96-2023-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	Unavailable Not reported for this period.	−EUR 3.7 million Exact value Exact value: -3698000 EUR 2023-01-01 – 2023-12-31: -3698000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIONYX Pharma · 2023-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Operating Cash Flow: -3698000 EUR Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: -3698000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2023-12-31/ESEF/FR/0/abionyxpharma-2023-12-31AR.zip#14785205 Filing: 969500785J7VIC5YPC96-2023-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	EUR 104,000 Exact value Exact value: 104000 EUR 2023-01-01 – 2023-12-31: 104000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIONYX Pharma · 2023-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Capital Expenditure: 104000 EUR Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 104000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2023-12-31/ESEF/FR/0/abionyxpharma-2023-12-31AR.zip#14793806 Filing: 969500785J7VIC5YPC96-2023-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	−EUR 3.8 million Calculation and evidence -3698000 − 104000 EUR Exact free cash flow: -3802000 EUR 2023-01-01 – 2023-12-31: -3698000 EUR · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 104000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIONYX Pharma · 2023-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Free cash flow: -3802000 EUR Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3698000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2023-12-31/ESEF/FR/0/abionyxpharma-2023-12-31AR.zip#14785205 Filing: 969500785J7VIC5YPC96-2023-12-31-ESEF-FR-0 Input fundies:CapitalExpenditure: 104000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2023-12-31/ESEF/FR/0/abionyxpharma-2023-12-31AR.zip#14793806 Filing: 969500785J7VIC5YPC96-2023-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	Unavailable Not reported for this period.	−EUR 3.63 million Exact value Exact value: -3634000 EUR 2024-01-01 – 2024-12-31: -3634000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIONYX Pharma · 2024-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Operating Cash Flow: -3634000 EUR Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: -3634000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9321697 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	EUR 68,000 Exact value Exact value: 68000 EUR 2024-01-01 – 2024-12-31: 68000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIONYX Pharma · 2024-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Capital Expenditure: 68000 EUR Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 68000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9330504 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	−EUR 3.7 million Calculation and evidence -3634000 − 68000 EUR Exact free cash flow: -3702000 EUR 2024-01-01 – 2024-12-31: -3634000 EUR · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 68000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIONYX Pharma · 2024-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Free cash flow: -3702000 EUR Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3634000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9321697 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0 Input fundies:CapitalExpenditure: 68000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9330504 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	Unavailable Not reported for this period.	−EUR 2.93 million Exact value Exact value: -2933000 EUR 2025-01-01 – 2025-12-31: -2933000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIONYX Pharma · 2025-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Operating Cash Flow: -2933000 EUR Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: -2933000 EUR (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9321047 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	EUR 242,000 Exact value Exact value: 242000 EUR 2025-01-01 – 2025-12-31: 242000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIONYX Pharma · 2025-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Capital Expenditure: 242000 EUR Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 242000 EUR (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9329846 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	−EUR 3.18 million Calculation and evidence -2933000 − 242000 EUR Exact free cash flow: -3175000 EUR 2025-01-01 – 2025-12-31: -2933000 EUR · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 242000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIONYX Pharma · 2025-12-31 ABIONYX Pharma (esef:969500785J7VIC5YPC96) Free cash flow: -3175000 EUR Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:39:20Z Snapshot: 287a9ac9f626ce12c73dc1d9c7c3e599a8dd205e83eff727a078e6252bdc129e Dimensions: Consolidated View: https://fundies.io/companies/esef/969500785J7VIC5YPC96?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2933000 EUR (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9321047 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0 Input fundies:CapitalExpenditure: 242000 EUR (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/969500785J7VIC5YPC96/2025-12-31/ESEF/FR/0/969500785J7VIC5YPC96-2024-12-31AR.zip#9329846 Filing: 969500785J7VIC5YPC96-2025-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

4 filings · 291 latest values · 291 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 969500785J7VIC5YPC96, esef:969500785J7VIC5YPC96

ABIONYX Pharma

Latest fiscal year

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation